Follow us

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

AGuIX®: an innovative nanodrug with the aim to improve radiotherapy treatment of cancer

NH Theraguix

EVENTS

PRESS RELEASE

Géraldine LE DUC, NH Theraguix

60% of cancer patients are treated by radiotherapy with an expected increase of 16% by 2025

However 48% of cancer patients receiving radiotherapy do not survive mainly related to unwanted damage of surrounding tissues and organs imposing dose limitations

In this context of high unmet medical need,
AGuIX® drug has the potential
to overcome these limitations

AGuIX® is an easy-to-use innovative drug that has the potential to fit well with multiple radiotherapy protocols and to be applicable to a wide range of cancer indications

AGuIX® drug selectively accumulates in tumors based on its small size after intravenous administration and excess is rapidly eliminated through the kidneys

AGuIX® drug concentrates numerous gadolinium elements in its structure that provide:

  • Imaging property by magnetic resonance imaging (MRI)
  • Therapeutic activity through its radioenhancing property

Thanks to this combination of pharmacological properties, the AGuIX® drug could offer
a better lifespan and quality of life for patients affected by cancer